Quotient Clinical entered an agreement with Phico Therapeutics under which Quotient will undertake a RapidFACT program to optimize nasal delivery of Phico’s SASPject PT1.2, an antibiotic protein technology offering a new approach for the treatment of serious life-threatening bacterial infections, including MRSA. RapidFACT will be used to screen alternative formulations designed to enhance nasal delivery, retention and efficacy of SASPject in intranasal S. aureus carriers. RapidFACT uses Q...